Healthcare
2 items across 1 edition. First seen Sat 12 Sep, last seen Sat 12 Sep.
- The study, published in Clinical Cancer Research on 11 September as "Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent Resection" (DOI 10.1158/1078-0432.ccr-25-4968), analysed tissue from 203 patients with pancreatic ductal adenocarcinoma.
- The AI measured "tissue shape, fragmentation and the degree to which the cancer and stroma were intermixed" on standard pathology slides. "High-risk patients had a 71% higher adjusted risk of recurrence" in one model and "more than twice the adjusted risk" in another, while "the amount of residual cancer alone did not reliably separate patients at higher and lower risk".
- High-risk spatial patterns "contained fewer immune cells within the cancer itself, with immune cells tending to collect around the tumor instead of entering it" — a mechanism, not just a correlation, and one that runs on slides hospitals already produce.
- Dr Ryan Carr said "the results are promising but need to be confirmed in prospective studies before this approach could be used to inform clinical decision-making". Mayo Clinic's own newsroom page blocked our fetcher, so the figures above are as Medical Xpress reports them.
- Omniscient announced on 11 September at 14:42 ET that Quicktome Deep Brain (DB) has received 510(k) clearance from the FDA, its third clearance.
- The company says the workflow localises leads, segments deep brain structures and maps white matter tracts within brain networks, for deep brain stimulation used in Parkinson's disease, essential tremor, dystonia and other movement disorders.
- The release states roughly 10,000 new DBS procedures are performed in the US each year — the scale against which any benefit would be measured.
- CEO Stephen Scheeler is quoted: "This is our third FDA clearance, and each one advances the same strategy: build the connectomic platform that becomes the standard across neuroscience care." A 510(k) clearance establishes substantial equivalence to a predicate device, not clinical benefit; the release reports no outcome data.